Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Angelberger

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|October 23, 2004
Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinomaS Li, M Peck-Radosavljevic, O Kienast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapyI Virgolini, P Patri, C Novotny, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|July 31, 2001
New trends in peptide receptor radioligandsI Virgolini, T Traub, C Novotny, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2000
Radiation synovectomy using 165Dy ferric-hydroxide and oxidative DNA damage in patients with different types of arthritisC Pirich, A Pilger, E Schwameis, et al.
International Journal of Cancer|March 29, 2001
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphyS Li, M Peck-Radosavljevic, E Koller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Current Pharmaceutical Design|August 13, 2002
Experience with indium-111 and yttrium-90-labeled somatostatin analogsI Virgolini, T Traub, C Novotny, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Endocrinology|October 28, 1999
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapyP M Smith-Jones, C Bischof, M Leimer, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|October 23, 2004
Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinomaS Li, M Peck-Radosavljevic, O Kienast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapyI Virgolini, P Patri, C Novotny, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|July 31, 2001
New trends in peptide receptor radioligandsI Virgolini, T Traub, C Novotny, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 25, 2000
Radiation synovectomy using 165Dy ferric-hydroxide and oxidative DNA damage in patients with different types of arthritisC Pirich, A Pilger, E Schwameis, et al.
International Journal of Cancer|March 29, 2001
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphyS Li, M Peck-Radosavljevic, E Koller, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Current Pharmaceutical Design|August 13, 2002
Experience with indium-111 and yttrium-90-labeled somatostatin analogsI Virgolini, T Traub, C Novotny, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Endocrinology|October 28, 1999
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapyP M Smith-Jones, C Bischof, M Leimer, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Pageof 11